Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

July 24, 2022

Study Completion Date

July 24, 2022

Conditions
Peritoneal Dialysis Associated PeritonitisPeritoneal Dialysis (PD)Peritoneal DialysisPeritoneal Dialysis, Continuous AmbulatoryMeropenemAztreonamAntibacterial AgentsIntraperitoneal AntibioticsKidney Failure, ChronicAnti-Bacterial AgentsDrug Therapy
Interventions
DRUG

Meropenem 1000 mg

Administration of meropenem after intraperitoneal administration via cycler-therapy in APD patients without peritonitis

DRUG

Aztreonam 2000 mg

Administration of aztreonam after intraperitoneal administration via cycler-therapy in APD patients without peritonitis

OTHER

automated peritoneal dialysis with following long time dwell

The cycler therapy, followed by a prolonged dwell, will be performed as outlined in the study protocol.

DIAGNOSTIC_TEST

Sampling

The sampling of blood, dialysate, and urine will be performed as outlined in the study protocol.

Trial Locations (1)

A-3100

UK St. Pölten, Sankt Pölten

All Listed Sponsors
collaborator

Karl Landsteiner University of Health Sciences

OTHER

collaborator

Medical University of Cologne

OTHER

collaborator

University Hospital St. Polten

OTHER

collaborator

University of Vienna

OTHER

lead

Karl Landsteiner Insitute for Nephrology and Haemato-Oncology

NETWORK

NCT07113574 - Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis | Biotech Hunter | Biotech Hunter